0.21(0.79%) Volume: 1,118,243 8:08PM EST| Market Cap : 6.29 B | Enterprise Value : 9.56 B | P/E (TTM) : 31.03 | P/B : 5.21 |
|---|
AXTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.18 |
NYSE:AXTA's Cash-to-Debt is ranked lower than
85% of the 1122 Companies in the Global Specialty Chemicals industry. ( Industry Median: 0.72 vs. NYSE:AXTA: 0.18 ) Ranked among companies with meaningful Cash-to-Debt only. |
NYSE:AXTA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.16 Max: 143.5 Current: 0.18 |
| Equity-to-Asset | 0.18 |
NYSE:AXTA's Equity-to-Asset is ranked lower than
94% of the 1092 Companies in the Global Specialty Chemicals industry. ( Industry Median: 0.57 vs. NYSE:AXTA: 0.18 ) Ranked among companies with meaningful Equity-to-Asset only. |
NYSE:AXTA'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17 Med: 0.18 Max: 0.58 Current: 0.18 |
| Debt-to-Equity | 3.21 |
NYSE:AXTA's Debt-to-Equity is ranked lower than
97% of the 931 Companies in the Global Specialty Chemicals industry. ( Industry Median: 0.39 vs. NYSE:AXTA: 3.21 ) Ranked among companies with meaningful Debt-to-Equity only. |
NYSE:AXTA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 2.9 Med: 3.21 Max: 3.46 Current: 3.21 |
| Debt-to-EBITDA | 4.85 |
NYSE:AXTA's Debt-to-EBITDA is ranked lower than
80% of the 913 Companies in the Global Specialty Chemicals industry. ( Industry Median: 2.12 vs. NYSE:AXTA: 4.85 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
NYSE:AXTA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.85 Med: 5.66 Max: 15.55 Current: 4.85 |
| Interest Coverage | 2.77 |
NYSE:AXTA's Interest Coverage is ranked lower than
88% of the 1021 Companies in the Global Specialty Chemicals industry. ( Industry Median: 29.84 vs. NYSE:AXTA: 2.77 ) Ranked among companies with meaningful Interest Coverage only. |
NYSE:AXTA'
s Interest Coverage Range Over the Past 10 Years
Min: 0.25 Med: 2.68 Max: No Debt Current: 2.77 |
| Piotroski F-Score: 7 |
|
| Altman Z-Score: 1.88 |
|
| Beneish M-Score: -2.49 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | 9.41 |
NYSE:AXTA's Operating Margin % is ranked higher than
59% of the 1107 Companies in the Global Specialty Chemicals industry. ( Industry Median: 8.34 vs. NYSE:AXTA: 9.41 ) Ranked among companies with meaningful Operating Margin % only. |
NYSE:AXTA'
s Operating Margin % Range Over the Past 10 Years
Min: 1.33 Med: 9.52 Max: 11.33 Current: 9.41 |
| Net Margin % | 4.41 |
NYSE:AXTA's Net Margin % is ranked lower than
69% of the 1106 Companies in the Global Specialty Chemicals industry. ( Industry Median: 5.82 vs. NYSE:AXTA: 4.41 ) Ranked among companies with meaningful Net Margin % only. |
NYSE:AXTA'
s Net Margin % Range Over the Past 10 Years
Min: -5.64 Med: 1.59 Max: 5.72 Current: 4.41 |
| ROE % | 16.06 |
NYSE:AXTA's ROE % is ranked higher than
56% of the 1107 Companies in the Global Specialty Chemicals industry. ( Industry Median: 9.43 vs. NYSE:AXTA: 16.06 ) Ranked among companies with meaningful ROE % only. |
NYSE:AXTA'
s ROE % Range Over the Past 10 Years
Min: -16.03 Med: 3.53 Max: 29.25 Current: 16.06 |
| ROA % | 3.05 |
NYSE:AXTA's ROA % is ranked lower than
73% of the 1134 Companies in the Global Specialty Chemicals industry. ( Industry Median: 4.78 vs. NYSE:AXTA: 3.05 ) Ranked among companies with meaningful ROA % only. |
NYSE:AXTA'
s ROA % Range Over the Past 10 Years
Min: -4.68 Med: 0.66 Max: 16.9 Current: 3.05 |
| ROC (Joel Greenblatt) % | 22.24 |
NYSE:AXTA's ROC (Joel Greenblatt) % is ranked higher than
73% of the 1130 Companies in the Global Specialty Chemicals industry. ( Industry Median: 14.65 vs. NYSE:AXTA: 22.24 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
NYSE:AXTA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3.14 Med: 19.06 Max: 70.59 Current: 22.24 |
| 3-Year Revenue Growth Rate | 4.10 |
NYSE:AXTA's 3-Year Revenue Growth Rate is ranked lower than
69% of the 1052 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.70 vs. NYSE:AXTA: 4.10 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
NYSE:AXTA'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.6 Med: -1.3 Max: 4.1 Current: 4.1 |
| 3-Year EBITDA Growth Rate | 5.90 |
NYSE:AXTA's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 980 Companies in the Global Specialty Chemicals industry. ( Industry Median: 7.60 vs. NYSE:AXTA: 5.90 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
NYSE:AXTA'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 4.4 Med: 6.8 Max: 29.4 Current: 5.9 |
| 3-Year EPS without NRI Growth Rate | 30.80 |
NYSE:AXTA's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 904 Companies in the Global Specialty Chemicals industry. ( Industry Median: 11.10 vs. NYSE:AXTA: 30.80 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
NYSE:AXTA'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: -46.5 Max: 30.8 Current: 30.8 |
| Lee Ainslie 59,840 sh (New) Mario Gabelli 10,200 sh (New) Wallace Weitz 757,450 sh (+288.44%) Robert Olstein 231,499 sh (+0.23%) Leucadia National 352,600 sh (+252.60%) Steven Cohen 856,943 sh (+3.21%) Caxton Associates 110,000 sh (+10.00%) Louis Moore Bacon 567,019 sh (+209.32%) Diamond Hill Capital 10,889,676 sh (+6.13%) Steven Romick 3,060,111 sh (+0.01%) Barrow, Hanley, Mewhinney & Strauss 6,993,205 sh (+0.18%) Jerome Dodson 673,680 sh (+22.49%) | Warren Buffett 23,324,000 sh (unchged) | First Eagle Investment Sold Out Chris Davis 8,883,246 sh (-7.25%) Jim Simons 179,300 sh (-74.23%) First Pacific Advisors 3,375,483 sh (-0.26%) Pioneer Investments 514,569 sh (-2.89%) Lou Simpson 32,179 sh (-99.58%) |
| Warren Buffett 24,264,000 sh (+4.03%) Leucadia National 382,600 sh (+8.51%) Caxton Associates 140,000 sh (+27.27%) Mario Gabelli 12,200 sh (+19.61%) Jim Simons 1,240,597 sh (+591.91%) | Wallace Weitz 757,450 sh (unchged) Robert Olstein 231,499 sh (unchged) Steven Romick 3,060,111 sh (unchged) Jerome Dodson 673,680 sh (unchged) | Lee Ainslie Sold Out Lou Simpson Sold Out Chris Davis 24,160 sh (-99.73%) Steven Cohen 376,400 sh (-56.08%) Louis Moore Bacon 134,541 sh (-76.27%) First Pacific Advisors 3,356,608 sh (-0.56%) Diamond Hill Capital 10,419,595 sh (-4.32%) Barrow, Hanley, Mewhinney & Strauss 6,662,136 sh (-4.73%) Pioneer Investments 226,818 sh (-55.92%) |
| Paul Tudor Jones 41,524 sh (New) Mario Gabelli 13,200 sh (+8.20%) Diamond Hill Capital 10,630,592 sh (+2.03%) Wallace Weitz 774,950 sh (+2.31%) Jim Simons 2,349,500 sh (+89.38%) | Steven Romick 3,060,111 sh (unchged) Jerome Dodson 673,680 sh (unchged) Warren Buffett 24,264,000 sh (unchged) | Leucadia National Sold Out Louis Moore Bacon Sold Out Caxton Associates Sold Out Robert Olstein 222,799 sh (-3.76%) Chris Davis 23,540 sh (-2.57%) Barrow, Hanley, Mewhinney & Strauss 6,470,169 sh (-2.88%) First Pacific Advisors 3,348,967 sh (-0.23%) Pioneer Investments 199,173 sh (-12.19%) Steven Cohen 240,500 sh (-36.11%) |
| Louis Moore Bacon 256,239 sh (New) Mario Gabelli 34,200 sh (+159.09%) Robert Olstein 265,700 sh (+19.26%) Wallace Weitz 816,675 sh (+5.38%) Diamond Hill Capital 11,074,847 sh (+4.18%) Steven Cohen 486,900 sh (+102.45%) | Jerome Dodson 673,680 sh (unchged) Chris Davis 23,540 sh (unchged) Steven Cohen 200,000 sh (unchged) Warren Buffett 24,264,000 sh (unchged) | Paul Tudor Jones Sold Out Steven Romick 2,741,581 sh (-10.41%) Jim Simons 1,718,000 sh (-26.88%) First Pacific Advisors 3,067,818 sh (-8.40%) Barrow, Hanley, Mewhinney & Strauss 6,040,100 sh (-6.65%) Pioneer Investments 120,032 sh (-39.73%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Chemicals » Specialty Chemicals NAICS: 325510 SIC: 2851 | |
|---|---|---|
| Compare: | XSWX:CLN, NSE:PIDILITIND, ISX:TPIA, XTER:LXS, LSE:CRDA, LSE:JMAT, MEX:ALFA A, NYSE:RPM, NYSE:CC, SZSE:300072, SZSE:002601, TSE:4613, XTER:BNR, ASX:ORI, SZSE:002466, NYSE:OLN, XPAR:AKE, XAMS:OCI, TSE:4182, NYSE:NEU » details | |
| Traded in other countries: | 9AX.Germany, 0U6C.UK, | |
| Headquarter Location: | USA |
Axalta (NYSE:AXTA) manufacturers paint and other coatings and designs systems for their application in automotive and industrial end markets. We are attracted to Axalta’s scale position as the #1 or #2 player in most of its business lines and the “sticky” nature of its customer base (once designed into a manufacturing line or aftermarket repair facility, the costs to switch to a new provider are very high). We believe the company has ample opportunity to grow organically through market share gains or thoughtful acquisitions.
From Wally Weitz's Hickory Fund third quarter 2017 shareholder letter.
Shares of Axalta (NYSE:AXTA), which makes paints and coatings for vehicles, declined in the third quarter. The company faced higher costs for raw materials, and in a period of sluggish demand for auto-mobile refinishing, had difficulty raising its prices. We sold this holding during the quarter and reallocated the capital to other positions.
From First Eagle Fund of America third quarter 2017 shareholder commentary.
| vs
industry |
vs
history |
||
|---|---|---|---|
| PE Ratio | 31.03 |
AXTA's PE Ratio is ranked lower than
88% of the 957 Companies in the Global Specialty Chemicals industry. ( Industry Median: 18.54 vs. AXTA: 31.03 ) Ranked among companies with meaningful PE Ratio only. |
AXTA'
s PE Ratio Range Over the Past 10 Years
Min: 25.85 Med: 109.64 Max: 382.11 Current: 31.03 |
| Forward PE Ratio | 18.94 |
AXTA's Forward PE Ratio is ranked lower than
81% of the 114 Companies in the Global Specialty Chemicals industry. ( Industry Median: 16.29 vs. AXTA: 18.94 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PE Ratio without NRI | 31.03 |
AXTA's PE Ratio without NRI is ranked lower than
88% of the 958 Companies in the Global Specialty Chemicals industry. ( Industry Median: 18.80 vs. AXTA: 31.03 ) Ranked among companies with meaningful PE Ratio without NRI only. |
AXTA'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.85 Med: 109.64 Max: 382.11 Current: 31.03 |
| Price-to-Owner-Earnings | 21.97 |
AXTA's Price-to-Owner-Earnings is ranked higher than
52% of the 541 Companies in the Global Specialty Chemicals industry. ( Industry Median: 22.77 vs. AXTA: 21.97 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
AXTA'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.28 Med: 22.15 Max: 33.94 Current: 21.97 |
| PB Ratio | 5.21 |
AXTA's PB Ratio is ranked lower than
90% of the 1099 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.83 vs. AXTA: 5.21 ) Ranked among companies with meaningful PB Ratio only. |
AXTA'
s PB Ratio Range Over the Past 10 Years
Min: 4.35 Med: 5.8 Max: 8.19 Current: 5.21 |
| PS Ratio | 1.39 |
AXTA's PS Ratio is ranked lower than
58% of the 1085 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.27 vs. AXTA: 1.39 ) Ranked among companies with meaningful PS Ratio only. |
AXTA'
s PS Ratio Range Over the Past 10 Years
Min: 1.15 Med: 1.65 Max: 2.09 Current: 1.39 |
| Price-to-Free-Cash-Flow | 18.09 |
AXTA's Price-to-Free-Cash-Flow is ranked higher than
61% of the 439 Companies in the Global Specialty Chemicals industry. ( Industry Median: 22.93 vs. AXTA: 18.09 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
AXTA'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.65 Med: 19.13 Max: 145.11 Current: 18.09 |
| Price-to-Operating-Cash-Flow | 12.95 |
AXTA's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 602 Companies in the Global Specialty Chemicals industry. ( Industry Median: 14.12 vs. AXTA: 12.95 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
AXTA'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.27 Med: 13.98 Max: 35.34 Current: 12.95 |
| EV-to-EBIT | 22.35 |
AXTA's EV-to-EBIT is ranked lower than
72% of the 986 Companies in the Global Specialty Chemicals industry. ( Industry Median: 14.73 vs. AXTA: 22.35 ) Ranked among companies with meaningful EV-to-EBIT only. |
AXTA'
s EV-to-EBIT Range Over the Past 10 Years
Min: 20.1 Med: 32.95 Max: 62.9 Current: 22.35 |
| EV-to-EBITDA | 12.04 |
AXTA's EV-to-EBITDA is ranked lower than
56% of the 1002 Companies in the Global Specialty Chemicals industry. ( Industry Median: 11.50 vs. AXTA: 12.04 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AXTA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.8 Med: 16.2 Max: 22.4 Current: 12.04 |
| EV-to-Revenue | 2.05 |
AXTA's EV-to-Revenue is ranked lower than
68% of the 1098 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.45 vs. AXTA: 2.05 ) Ranked among companies with meaningful EV-to-Revenue only. |
AXTA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8 Med: 2.4 Max: 2.9 Current: 2.05 |
| PEG Ratio | 1.73 |
AXTA's PEG Ratio is ranked lower than
82% of the 577 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.67 vs. AXTA: 1.73 ) Ranked among companies with meaningful PEG Ratio only. |
AXTA'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 18.71 Current: 1.73 |
| Current Ratio | 2.22 |
AXTA's Current Ratio is ranked higher than
62% of the 1116 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.90 vs. AXTA: 2.22 ) Ranked among companies with meaningful Current Ratio only. |
AXTA'
s Current Ratio Range Over the Past 10 Years
Min: 1.81 Med: 2.04 Max: 2.22 Current: 2.22 |
| Quick Ratio | 1.63 |
AXTA's Quick Ratio is ranked higher than
61% of the 1116 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.37 vs. AXTA: 1.63 ) Ranked among companies with meaningful Quick Ratio only. |
AXTA'
s Quick Ratio Range Over the Past 10 Years
Min: 1.18 Med: 1.48 Max: 1.63 Current: 1.63 |
| Days Inventory | 72.43 |
AXTA's Days Inventory is ranked lower than
59% of the 1075 Companies in the Global Specialty Chemicals industry. ( Industry Median: 64.18 vs. AXTA: 72.43 ) Ranked among companies with meaningful Days Inventory only. |
AXTA'
s Days Inventory Range Over the Past 10 Years
Min: 29.31 Med: 71.77 Max: 76.56 Current: 72.43 |
| Days Sales Outstanding | 66.91 |
AXTA's Days Sales Outstanding is ranked higher than
51% of the 1082 Companies in the Global Specialty Chemicals industry. ( Industry Median: 68.33 vs. AXTA: 66.91 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AXTA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.05 Med: 58.36 Max: 66.91 Current: 66.91 |
| Days Payable | 61.43 |
AXTA's Days Payable is ranked higher than
58% of the 1061 Companies in the Global Specialty Chemicals industry. ( Industry Median: 56.72 vs. AXTA: 61.43 ) Ranked among companies with meaningful Days Payable only. |
AXTA'
s Days Payable Range Over the Past 10 Years
Min: 48.53 Med: 58.83 Max: 67.06 Current: 61.43 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.30 |
AXTA's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 627 Companies in the Global Specialty Chemicals industry. ( Industry Median: -3.80 vs. AXTA: 0.30 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AXTA'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.7 Med: -1.3 Max: 0.3 Current: 0.3 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Median-PS-Value | 0.83 |
AXTA's Price-to-Median-PS-Value is ranked higher than
62% of the 1029 Companies in the Global Specialty Chemicals industry. ( Industry Median: 1.08 vs. AXTA: 0.83 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AXTA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.73 Med: 0.93 Max: 1.1 Current: 0.83 |
| Earnings Yield (Greenblatt) % | 4.50 |
AXTA's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 1133 Companies in the Global Specialty Chemicals industry. ( Industry Median: 5.92 vs. AXTA: 4.50 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AXTA'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6 Med: 3 Max: 5 Current: 4.5 |
| Revenue (TTM) (Mil) $ | 4,696.00 |
|---|---|
| EPS (TTM) $ | 0.86 |
| Beta | 1.11 |
| Volatility | 20.38% |
| 52-Week Range $ | 21.58 - 33.30 |
| Shares Outstanding (Mil) | 235.60 |
| Dec19 | Dec20 | Dec21 | |
|---|---|---|---|
| Revenue (Mil $) | 4,809 | 4,984 | 5,119 |
| EBIT (Mil $) | 585 | 629 | 682 |
| EBITDA (Mil $) | 966 | 1,014 | 1,084 |
| EPS ($) | 1.41 | 1.59 | 1.80 |
| EPS without NRI ($) | 1.41 | 1.59 | 1.80 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP